GSK’s (GSK) “Buy” Rating Reiterated at Shore Capital

Shore Capital reiterated their buy rating on shares of GSK (LON:GSK) in a research note issued to investors on Wednesday morning, MarketBeat Ratings reports.

GSK has been the subject of several other reports. Barclays reaffirmed an equal weight rating and issued a GBX 1,725 ($21.67) price objective on shares of GSK in a report on Monday, April 8th. Deutsche Bank Aktiengesellschaft reaffirmed a buy rating and set a GBX 1,950 ($24.49) price target on shares of GSK in a research note on Wednesday, April 17th. Finally, Berenberg Bank boosted their target price on GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the company a buy rating in a research note on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, GSK has an average rating of Hold and a consensus target price of GBX 1,675.63 ($21.05).

GSK Stock Up 0.3 %

GSK opened at GBX 1,733.50 ($21.77) on Wednesday. The company has a 50 day moving average of GBX 1,662.06 and a 200 day moving average of GBX 1,556.29. The company has a market cap of £70.90 billion, a PE ratio of 1,444.58, a price-to-earnings-growth ratio of 1.12 and a beta of 0.27. GSK has a 12 month low of GBX 1,302.60 ($16.36) and a 12 month high of GBX 1,739.56 ($21.85). The company has a current ratio of 0.88, a quick ratio of 0.73 and a debt-to-equity ratio of 140.82.

GSK Cuts Dividend

The firm also recently declared a dividend, which will be paid on Thursday, July 11th. Investors of record on Thursday, May 16th will be issued a dividend of GBX 15 ($0.19) per share. The ex-dividend date is Thursday, May 16th. This represents a yield of 0.9%. GSK’s dividend payout ratio is presently 5,333.33%.

Insiders Place Their Bets

In other news, insider Urs Rohner bought 434 shares of GSK stock in a transaction on Wednesday, March 20th. The shares were purchased at an average price of GBX 1,662 ($20.88) per share, for a total transaction of £7,213.08 ($9,060.52). In related news, insider Emma Walmsley sold 139,792 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.83), for a total value of £2,317,751.36 ($2,911,382.19). Also, insider Urs Rohner purchased 434 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was acquired at an average price of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,060.52). Company insiders own 1.77% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.